UNLABELLED: Abnormalities of fatty acid metabolism in the heart presage contractile dysfunction and arrhythmias. This study was performed to determine whether myocardial fatty acid metabolism could be quantified noninvasively using PET and 1-(11)C-palmitate. METHODS: Anesthetized dogs were studied during control conditions; during administration of dobutamine; after oxfenicine; and during infusion of glucose. Dynamic PET data after administration of 1-(11)C-palmitate were fitted to a four-compartment mathematical model. RESULTS: Modeled rates of palmitate utilization correlated closely with directly measured myocardial palmitate and total long-chain fatty acid utilization (r = 0.93 and 0.96, respectively, p < 0.001 for each) over a wide range of arterial fatty acid levels and altered patterns of myocardial substrate use (fatty acid extraction fraction ranging from 1% to 56%, glucose extraction fraction from 1% to 16% and myocardial fatty acid utilization from 1 to 484 nmole/g/ min). The percent of fatty acid undergoing oxidation could also be measured. CONCLUSION: The results demonstrate the ability to quantify myocardial fatty acid utilization with PET. The approach is readily applicable for the determination of fatty acid metabolism noninvasively in patients.
UNLABELLED: Abnormalities of fatty acid metabolism in the heart presage contractile dysfunction and arrhythmias. This study was performed to determine whether myocardial fatty acid metabolism could be quantified noninvasively using PET and 1-(11)C-palmitate. METHODS: Anesthetized dogs were studied during control conditions; during administration of dobutamine; after oxfenicine; and during infusion of glucose. Dynamic PET data after administration of 1-(11)C-palmitate were fitted to a four-compartment mathematical model. RESULTS: Modeled rates of palmitate utilization correlated closely with directly measured myocardial palmitate and total long-chain fatty acid utilization (r = 0.93 and 0.96, respectively, p < 0.001 for each) over a wide range of arterial fatty acid levels and altered patterns of myocardial substrate use (fatty acid extraction fraction ranging from 1% to 56%, glucose extraction fraction from 1% to 16% and myocardial fatty acid utilization from 1 to 484 nmole/g/ min). The percent of fatty acid undergoing oxidation could also be measured. CONCLUSION: The results demonstrate the ability to quantify myocardial fatty acid utilization with PET. The approach is readily applicable for the determination of fatty acid metabolism noninvasively in patients.
Authors: Robert J Gropler; Rob S B Beanlands; Vasken Dilsizian; E Douglas Lewandowski; Flordeliza S Villanueva; Maria Cecilia Ziadi Journal: J Nucl Med Date: 2010-05-01 Impact factor: 10.057
Authors: Zhude Tu; Shihong Li; Terry L Sharp; Pilar Herrero; Carmen S Dence; Robert J Gropler; Robert H Mach Journal: Bioconjug Chem Date: 2010-11-11 Impact factor: 4.774
Authors: Lisa de las Fuentes; Pablo F Soto; Brian P Cupps; Michael K Pasque; Pilar Herrero; Robert J Gropler; Alan D Waggoner; Victor G Dávila-Román Journal: J Nucl Cardiol Date: 2006 May-Jun Impact factor: 5.952
Authors: Linda R Peterson; Pablo F Soto; Pilar Herrero; Kenneth B Schechtman; Carmen Dence; Robert J Gropler Journal: J Nucl Cardiol Date: 2007-06-27 Impact factor: 5.952
Authors: Hugo W A M de Jong; Luuk J Rijzewijk; Mark Lubberink; Rutger W van der Meer; Hildo J Lamb; Jan W A Smit; Michaëla Diamant; Adriaan A Lammertsma Journal: Eur J Nucl Med Mol Imaging Date: 2009-01-27 Impact factor: 9.236
Authors: Pablo F Soto; Pilar Herrero; Kenneth B Schechtman; Alan D Waggoner; Jeffrey M Baumstark; Ali A Ehsani; Robert J Gropler Journal: Am J Physiol Heart Circ Physiol Date: 2008-06-20 Impact factor: 4.733
Authors: Pilar Herrero; Janet McGill; Donna S Lesniak; Carmen S Dence; Shalonda W Scott; Zulfia Kisrieva-Ware; Robert J Gropler Journal: J Nucl Cardiol Date: 2008 Nov-Dec Impact factor: 5.952